SITE008-0058

SITE008 (KOR) › SITE008-0058

SITE008-0058

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2025-11-06

enrolled

AEs

1

Serious

1

Dropout signal

–

Adverse events

1

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 261); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.